GlassScriptPhysician profile
Kendall Syms
NPI 1467102004
$4,996.95
in general payments reported to CMS, 2019-2025
24 companies · $2,921 in 2025
The $2,921 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,076 · 2025: $2,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,451 · Education: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,450.98 |
| Education | $545.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,512.06 | 2024-2025 | |
| Janssen Biotech, INC. | $528.40 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $446.69 | 2024-2025 | |
| Incyte Corporation | $388.19 | 2024-2025 | Opzelura |
| Amgen INC. | $268.78 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $222.49 | 2024-2025 | Nemluvio |
| Ucb, INC. | $210.89 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $185.05 | 2024-2025 | |
| Lilly USA, LLC | $176.46 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $163.74 | 2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $137.28 | 2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $117.80 | 2025 | Dupixent |
| Pfizer INC. | $112.97 | 2024-2025 | |
| Organon LLC | $93.05 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $92.00 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $90.35 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.59 | 2024-2025 | Siliq, Targretin, Duobrii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.62 | 2025 | Spevigo |
| Revance Therapeutics, INC. | $26.98 | 2025 | Daxxify |
| Tempus Ai, INC | $24.67 | 2024 | |
| Verrica Pharmaceuticals INC. | $24.66 | 2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $22.78 | 2025 | Zoryve |
| Journey Medical Corporation | $18.74 | 2025 | |
| Botanix Sb INC | $16.71 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Syms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.